These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 38074736)

  • 21. [Cost-effectiveness analysis of quadrivalent influenza vaccination for older adults aged 60 and above in mainland China].
    Yan H; Yang J; Chen ZY; Gong H; Zhong GJ; Yu HJ
    Zhonghua Yi Xue Za Zhi; 2021 Aug; 101(30):2405-2412. PubMed ID: 34404135
    [No Abstract]   [Full Text] [Related]  

  • 22. Cost-effectiveness analysis of the implementation of a National Immunization Program for rotavirus vaccination in a country with a low rotavirus gastroenteritis-related mortality: A South Korean study.
    Lee H; Park SY; Clark A; Debellut F; Pecenka C; Kim DS; Kim HM; Kim JH; Cho H; Kim AY; Lee M; Jung SY; Seong BL; Kang HY
    Vaccine; 2019 Aug; 37(35):4987-4995. PubMed ID: 31326252
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost effectiveness analysis comparing varying booster intervals of vaccination policies to address COVID-19 situation in Thailand, 2023.
    Mahasing C; Suphanchaimat R; Teekasap P; Nittayasoot N; Wongsanuphat S; Thammawijaya P
    PLoS One; 2024; 19(9):e0310427. PubMed ID: 39288199
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of COVID-19 vaccination: A systematic review.
    Fu Y; Zhao J; Han P; Zhang J; Wang Q; Wang Q; Wei X; Yang L; Ren T; Zhan S; Li L
    J Evid Based Med; 2023 Jun; 16(2):152-165. PubMed ID: 37186130
    [TBL] [Abstract][Full Text] [Related]  

  • 25. mRNA-based COVID-19 booster vaccination is highly effective and cost-effective in Australia.
    Li R; Liu H; Fairley CK; Ong JJ; Guo Y; Lu P; Zou Z; Xie L; Zhuang G; Li Y; Shen M; Zhang L
    Vaccine; 2023 Apr; 41(15):2439-2446. PubMed ID: 36781332
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact and cost-effectiveness analyses of vaccination for prevention of respiratory syncytial virus disease among older adults in Ontario: A Canadian Immunization Research Network (CIRN) study.
    Shoukat A; Bawden CE; Röst G; LeBlanc JJ; Galvani AP; Langley JM; Moghadas SM
    Vaccine; 2024 Mar; 42(7):1768-1776. PubMed ID: 38368226
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost Effectiveness of Quadrivalent Influenza Vaccines Compared with Trivalent Influenza Vaccines in Young Children and Older Adults in Korea.
    Kim YK; Song JY; Jang H; Kim TH; Koo H; Varghese L; Han E
    Pharmacoeconomics; 2018 Dec; 36(12):1475-1490. PubMed ID: 30251078
    [TBL] [Abstract][Full Text] [Related]  

  • 28. How the Timing of Annual COVID-19 Vaccination of Nursing Home Residents and Staff Affects Its Value.
    Bartsch SM; Weatherwax C; Wasserman MR; Chin KL; Martinez MF; Velmurugan K; Singh RD; John DC; Heneghan JL; Gussin GM; Scannell SA; Tsintsifas AC; O'Shea KJ; Dibbs AM; Leff B; Huang SS; Lee BY
    J Am Med Dir Assoc; 2024 Apr; 25(4):639-646.e5. PubMed ID: 38432644
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study.
    Cody P; Tobe K; Abe M; Elbasha EH
    BMC Infect Dis; 2021 Jan; 21(1):11. PubMed ID: 33407188
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Cost-effective analysis of seasonal influenza vaccine in elderly Chinese population].
    Chen C; Liu GE; Wang MJ; Gao TF; Jia HP; Yang H; Feng LZ
    Zhonghua Yu Fang Yi Xue Za Zhi; 2019 Oct; 53(10):993-999. PubMed ID: 31607044
    [No Abstract]   [Full Text] [Related]  

  • 31. Public health impact and cost-effectiveness of gonorrhoea vaccination: an integrated transmission-dynamic health-economic modelling analysis.
    Whittles LK; Didelot X; White PJ
    Lancet Infect Dis; 2022 Jul; 22(7):1030-1041. PubMed ID: 35427491
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Developing a Framework for Pandemic COVID-19 Vaccine Allocation: a Modified Delphi Consensus Study in Korea.
    Choi MJ; Choi WS; Seong H; Choi JY; Kim JH; Kim YJ; Cho EY; Kim DH; Park H; Lee H; Kim NJ; Song JY; Cheong HJ; Kim SI; Peck KR
    J Korean Med Sci; 2021 Jun; 36(23):e166. PubMed ID: 34128597
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The cost-effectiveness of starting 23-valent pneumococcal polysaccharide vaccine and influenza vaccination at 50 vs. 65 years: A comparative modelling study.
    Ding H; Huang J; Ngai CH; Sun Q; Kwok KO; Wang HH; Chong M; Wong MC
    Vaccine; 2022 Feb; 40(9):1282-1288. PubMed ID: 35094867
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of human papillomavirus vaccination in Germany.
    Damm O; Horn J; Mikolajczyk RT; Kretzschmar MEE; Kaufmann AM; Deleré Y; Ultsch B; Wichmann O; Krämer A; Greiner W
    Cost Eff Resour Alloc; 2017; 15():18. PubMed ID: 28878573
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness analysis of influenza vaccination during pregnancy in Japan.
    Hoshi SL; Shono A; Seposo X; Okubo I; Kondo M
    Vaccine; 2020 Oct; 38(46):7363-7371. PubMed ID: 33020012
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tetanus, diphtheria and acellular pertussis (Tdap) vaccine for prevention of pertussis among adults aged 19 years and older in the United States: A cost-effectiveness analysis.
    Cho BH; Acosta AM; Leidner AJ; Faulkner AE; Zhou F
    Prev Med; 2020 May; 134():106066. PubMed ID: 32199910
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical outcomes and cost-effectiveness of COVID-19 vaccination in South Africa.
    Reddy KP; Fitzmaurice KP; Scott JA; Harling G; Lessells RJ; Panella C; Shebl FM; Freedberg KA; Siedner MJ
    Nat Commun; 2021 Oct; 12(1):6238. PubMed ID: 34716349
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost effectiveness and budget impact of universal varicella vaccination in Russia.
    Marijam A; Safonova E; Scherbakov M; Shpeer E; Van Oorschot D; Rudakova A; Tatochenko V; Briko N
    Hum Vaccin Immunother; 2022 Nov; 18(5):2045152. PubMed ID: 35258445
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Case for Adolescent HIV Vaccination in South Africa: A Cost-Effectiveness Analysis.
    Moodley N; Gray G; Bertram M
    Medicine (Baltimore); 2016 Jan; 95(4):e2528. PubMed ID: 26825890
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical impact and cost-effectiveness of the updated COVID-19 mRNA Autumn 2023 vaccines in Germany.
    Joshi K; Scholz S; Maschio M; Kohli M; Lee A; Fust K; Ultsch B; Van de Velde N; Beck E
    J Med Econ; 2024; 27(1):39-50. PubMed ID: 38050685
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.